The effect of thermal insult to ocular tissue was first recorded in Western literature over two millennia ago. During the early scientific period and the ensuing eras, our understanding of this phenomenon, as well as our ability to accurately deliver dose-controlled therapeutic thermal energy to retinal tissue, have improved greatly. Since their commercial introduction in 1970, ophthalmic photocoagulation laser systems have been playing a cardinal role in the treatment and/or management of various ocular pathologies, predominantly though not limited to, retinal pathologies. Seminal studies, such as the Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS), have solidified the role of such tools in the ophthalmologist's therapeutic armamentarium; and to this day, as either stand-alone treatment or in combination with pharmacological agents, retinal laser therapy is recognised as the 'gold standard' for treating diabetic macular oedema (DME) and proliferative diabetic retinopathy (PDR). The continuous elucidation of the role that the retinal pigmented epithelium (RPE) plays in the emergence of retinal pathologies has prompted researchers and clinicians to further investigate selective RPE treatments -featuring significantly reduced or altogether devoid of collateral thermal damage to inner neural retinal structures with limited regenerative capacity. The convergence of electronic dosimetry, diagnostics imaging and new therapeutic laser modalities into a singular entity may serve as the technological platform for successfully employing such therapies in the near future.
the works of Cordes 6 (1944) 
Early Non-laser Photocoagulation Technology
The proverbial father of modern photocoagulation was
German ophthalmologist Gerhard (Gerd) Meyer-Schwickerath.
Meyer-Schwickerath observed the existence of scars in the retinas of patients who had been exposed to the solar eclipse of 10 July 1945.
He noted that the observed scars resembled such that are formed following surface diathermy. To employ the technique in a controlled manner, Meyer-Schwickerath constructed a Galilean telescope connected to a mirror and utilised it to focus sunlight onto the retina. 10 However, this novel approach suffered from numerous flaws, predominantly the reliance on external weather conditions, the lengthy exposure time needed to achieve the desired clinical outcome and the ability to control the accurate location and spot size of the burn. Recognising these challenges, Meyer-Schwickerath pursued the development of a coagulator equipped with artificial light source. In cooperation with Carl Zeiss Laboratories, a xenon arc lamp was constructed and came into use as the first commercial non-laser retina coagulator. However, the xenon arc lamp was not bereft of challenges either, such as long exposure times of 250-1,000 milliseconds (ms), a wavelength encompassing the entire range of 400-1,600 nanometres (nm), very large spot sizes in the range of 1000 microns (μm) and significant discomfort to the patient during treatment and post-operatively.
The Laser Era
The 
Multi-wavelength Lasers
In the mid-1970s the first tunable dye lasers became commercially 
Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study
The significance of the argon laser for the treatment of diabetic retinopathy was first demonstrated by the Diabetic Retinopathy Study (DRS), 13, 14 which has set the current standard of care for proliferative diabetic retinopathy, followed by the Early Treatment Diabetic Retinopathy Study (ETDRS), [15] [16] [17] [18] [19] [20] which has set the current standard of care for diabetic macular oedema. 
The Evolution of Retinal Laser Technology and Retinal Photocoagulation as Therapeutic Modality
E U R O P E A N O P H T H A L M I C R E V I E W
The Semiconductor Era
The first viable and commercially successful alternatives to gas-based lasers (e.g. argon and krypton), or liquid-based lasers (e.g. dye) came in the early 1990s, with the introduction of the first infrared diode lasers (Iris Corporation, now Iridex, Mountain View, CA, US) emitting in the range of 810 nm. Diode infrared lasers offered several advantages compared with gas-based lasers, such as reduced scatter (allowing better penetration through occluded media, such as cataracts and vitreous haemorrhage) and deeper choroidal penetration for targeting retinal and choroidal tumours. 22 However, similar to ruby lasers, absorption in the target tissue was sub-optimal (estimated at 20 %) compared with more than 90 % in argon green lasers, 23 and treatments also resulted in significant patient discomfort due to the longer exposure time and higher energy required to achieve clinical endpoints.
Modern Laser Consoles and Modified Early Treatment Diabetic Retinopathy Study
Since 
Reduced Fluence, Sub-threshold and Selective Laser Treatments
Micropulse mode was initially introduced using 810 nm (infrared) laser wavelength, and more recently incorporated into 532 nm (green) and 577 nm (yellow) wavelengths. In micropulse mode, continuous wave laser energy is electronically 'chopped' to create short (microsecond) 'on' and 'off' pulses. The length of the pulse can be determined by changing the duty cycle. The laser lesions are sub-visual (i.e. in principle, no visible burn is evident on the retina during treatment). However, even at the lowest setting, the pulse duration is longer than the retinal pigmented epithelium (RPE) thermal relaxation time and thus the term 'sub-threshold'
should be used more conservatively.
The major published studies (in small series of patients) are predominantly using the 810 nm wavelength. 31 A recent paper compared treatment with conventional laser with normal-density sub-threshold diode-laser micropulse (ND-SDM) (two spots apart) and high-density sub-threshold diode-laser micropulse (HD-SDM) (confluent treatment). 32 At 12 months, the HD-SDM group showed higher improvement in best corrected visual acuity (BCVA), followed 
